FORWARD FEATURES CALENDAR

VC

Maven VCTs invest a further GBP500,000 in GENinCode as company goes to IPO

Maven Capital Partners (Maven), has invested a further GBP500,000 in GENinCode, a genetic testing company specialising in the risk assessment and prediction of cardiovascular disease.  This funding package comes as the company completes its IPO, raising an additional GBP17 million gross and listing on AIM with a market capitalisation of

NavigatorCRE secures GBP12.5m in Series A funding round

NavigatorCRE, a commercial real estate data analytics SaaS platform, has completed a GBP12.5 million Series A funding round led by Fulcrum Equity Partners.  Also including participation by existing investors, the round paves the way for the Seattle based start-up to now enter the UK commercial real estate market. NavigatorCRE has

Vala launches new sustainable EIS fund

Vala Capital has invested in three fast-growth start-ups with sustainable strategies after successfully completing its first funding round for its new Sustainable Growth EIS. The company plans to raise GBP15 million for the sustainable EIS over the next two years and, having raised its target of GBP1.2 million for the

EmergeVest invests in neobank Lucy

EmergeVest, a Hong Kong-based growth-oriented private equity investment group, has invested in Lucy, a neobank focused on women entrepreneurs, through seed funding. In addition, Dr Jessica Bruser of EmergeVest has joined Lucy’s board of directors.  Lucy will use the proceeds of this funding round to invest in its tech platform,

O’Melveny advises Spectro Cloud in USD20m Series A funding

O’Melveny has advised Spectro Cloud, a next-generation Kubernetes enterprise management platform, in in the completion of a USD20 million Series A funding. The financing round was led by Stripes, a prominent investor in software and consumer products. Among investors funding the Series A raise were T-Mobile Ventures and Alter Venture

Topas Therapeutics extends Series B by EUR18m to EUR40m total

Topas Therapeutics GmbH (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced that the Company has successfully extended its Series B round with an additional EUR18 million (~USD22 million) raised, bringing the total for this financing to EUR40

Events

12 November, 2026 – 5:00 pm

Directory Listings